America To Buy Enough of Pfizer’s COVID-19 Pills for 10 Million People
America To Buy Enough of , Pfizer’s COVID-19 Pills, for 10 Million People.
'The New York Times' reports the
Biden administration intends to buy
more than five billion dollars worth
of Pfizer's antiviral COVID-19 pill.
'The New York Times' reports the
Biden administration intends to buy
more than five billion dollars worth
of Pfizer's antiviral COVID-19 pill.
Pfizer will reportedly
increase the production of its coronavirus pill early next year.
Federal health officials say the pill
may be a vital weapon against
the spread of COVID-19.
In trials conducted on unvaccinated individuals,
the pill was 89% effective in reducing the risk of hospitalization and death.
However, it must be taken alongside
another antiviral drug, ritonavir.
As winter approaches, some within
the Biden administration believe the
worst of the pandemic is behind us.
As winter approaches, some within
the Biden administration believe the
worst of the pandemic is behind us.
Public health experts say that although the Delta variant left a trail of death and disease in the U.S., it also
raised natural immunity in much of the population.
Even without
these pills, those
numbers are
going down. , Dr. David Dowdy, professor of epidemiology at Johns Hopkins Bloomberg School of Public Health, via 'The New York Times'.
Pfizer asked the Food and Drug Administration on November 16 for authorization to administer the pills to unvaccinated people who are considered high-risk.
The company reportedly expects to
produce enough of its pill for
180,000 citizens by the end of this year.
The company reportedly expects to
produce enough of its pill for
180,000 citizens by the end of this year.
In the first half of 2022, Pfizer
expects to have enough pills
to treat 21 million people
'The New York Times' reports the
Biden administration intends to buy
more than five billion dollars worth
of Pfizer's antiviral COVID-19 pill.
'The New York Times' reports the
Biden administration intends to buy
more than five billion dollars worth
of Pfizer's antiviral COVID-19 pill.
Pfizer will reportedly
increase the production of its coronavirus pill early next year.
Federal health officials say the pill
may be a vital weapon against
the spread of COVID-19.
In trials conducted on unvaccinated individuals,
the pill was 89% effective in reducing the risk of hospitalization and death.
However, it must be taken alongside
another antiviral drug, ritonavir.
As winter approaches, some within
the Biden administration believe the
worst of the pandemic is behind us.
As winter approaches, some within
the Biden administration believe the
worst of the pandemic is behind us.
Public health experts say that although the Delta variant left a trail of death and disease in the U.S., it also
raised natural immunity in much of the population.
Even without
these pills, those
numbers are
going down. , Dr. David Dowdy, professor of epidemiology at Johns Hopkins Bloomberg School of Public Health, via 'The New York Times'.
Pfizer asked the Food and Drug Administration on November 16 for authorization to administer the pills to unvaccinated people who are considered high-risk.
The company reportedly expects to
produce enough of its pill for
180,000 citizens by the end of this year.
The company reportedly expects to
produce enough of its pill for
180,000 citizens by the end of this year.
In the first half of 2022, Pfizer
expects to have enough pills
to treat 21 million people